TP53 and breast carcinoma: The role of C16orf72/HAPSTR1 in a p53 regulatory mechanism is further supported by the mutual exclusivity of TP53 genetic alteration and C16orf72/HAPSTR1 amplification/gains, which is observed in up to 55% of breast cancer genomes.